Kineta, Inc. (KANT)

Market Cap	4.55M
Revenue (ttm)	n/a
Net Income	-8.57M
EPS	-0.69
Shares Out	13.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	360
Average Volume	23,292
Open	0.3041
Previous Close	0.2900
Day's Range	0.3041 - 0.3370
52-Week Range	0.1806 - 1.1500
Beta	-2.72
RSI	61.34
Earnings Date	Aug 8, 2025

About Kineta

Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients’ lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 5
• Stock Exchange: OTCMKTS
• Ticker Symbol: KANT